Bioventrix
Mansfield, US · Delaware corporation · 1 known investors
BioVentrix is a medical device company that develops less invasive therapies to treat heart failure by reconstructing the dilated left ventricle using myocardial micro-anchor implants. The company serves cardiothoracic surgeons and patients with ischemic heart failure.
Founders & leadership
DR
DAVID RICHMONDinExecutive
SC
STEVE CHARTIERinExecutive
JD
JAMES DILLONExecutive
OB
ORI BEN-YEHUDAExecutive
WA
WILLIAM ABBOTTinExecutive
MK
Miller KenExecutive
Board
MT
Michael TaglichBoard director
AH
ANDREW HINSONBoard director
BC
BIHUA CHENBoard director
RW
RAPHAEL WISNIEWSKIBoard director
RS
RINDA SAMABoard director
PS
Paul SeidBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$173.3M disclosed across 16 of 17 rounds · 2012–2026
▶$705KraisedApr 2026 · 9 investors · OtherRule 506(b)
▶$705KraisedApr 2026 · 9 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- William T. AbrahamDirector
- Rishi PuriDirector
- Steven ChartierExecutive Officer, Director
- David RichmondExecutive Officer, Director
- Offering amount
- $6M
- Amount sold
- $705K
- Proceeds to insiders
- $500K
- First sale
- Apr 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.7MraisedNov 2025 · 45 investors · OtherRule 506(b)
▶$6.7MraisedNov 2025 · 45 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- WILLIAM ABRAHAMDirector
- STEVEN CHARTIERExecutive Officer, Director
- RISHI PURIDirector
- DAVID RICHMONDExecutive Officer, Director
- MICHAEL TAGLICHDirector
- MARK RAVICHDirector
- Offering amount
- $12M
- Amount sold
- $6.7M
- Sales commissions
- $120K
- Proceeds to insiders
- $800K
- Placement agents
- FINALIS SECURITIES LLC, THIRD500, LLC, THE BENCHMARK COMPANY, LLC
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3MraisedAug 2024 · 21 investors · OtherRule 506(b)
▶$3MraisedAug 2024 · 21 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- MICHAEL TAGLICHDirector
- DAVID RICHMONDExecutive Officer, Director
- Offering amount
- $3M
- Amount sold
- $3M
- Proceeds to insiders
- $300K
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.7MraisedApr 2023 · 12 investors · OtherRule 506(b)
▶$12.7MraisedApr 2023 · 12 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- RAYMOND COHENDirector
- STEVE CHARTIERExecutive Officer
- JAMES DILLONExecutive Officer, Director
- DAVID RICHMONDDirector
- ANDREW HINSONDirector
- ANDREW COATSDirector
- BIHUA CHENDirector
- MICHAEL TAGLICHDirector
- RAPHAEL WISNIEWSKIDirector
- RINDA SAMADirector
- ORI BEN-YEHUDAExecutive Officer
- WILLIAM ABBOTTExecutive Officer
- CHRISTOPHER WOLFFExecutive Officer
- Offering amount
- $15.7M
- Amount sold
- $12.7M
- Proceeds to insiders
- $1.2M
- First sale
- Mar 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedJan 2023 · 18 investors · OtherRule 506(b)
▶$2MraisedJan 2023 · 18 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- STEVE CHARTIERExecutive Officer
- MICHAEL TAGLICHDirector
- ANDREW COATSDirector
- DAVID RICHMONDDirector
- RAYMOND COHENDirector
- ANDREW HINSONDirector
- JAMES DILLONExecutive Officer, Director
- LAUREN BAKERDirector
- WILLIAM ABBOTTExecutive Officer
- GEORGE FAZIODirector
- MARK RAVICHDirector
- CHRISTOPHER WOLFFExecutive Officer
- STEVEN HEALYDirector
- RINDA SAMADirector
- Offering amount
- $3M
- Amount sold
- $2M
- Sales commissions
- $240K
- Proceeds to insiders
- $2M
- Placement agents
- TAGLICH BROTHERS, INC.
- First sale
- Jan 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedApr 2022 · 1 investors · OtherRule 506(b)
▶$1MraisedApr 2022 · 1 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- STEVE CHARTIERExecutive Officer
- RINDA SAMADirector
- JAMES DILLONExecutive Officer, Director
- CHRISTOPHER WOLFFExecutive Officer
- GEORGE FAZIODirector
- STEVEN HEALYDirector
- MARK RAVICHDirector
- ANDREW COATSDirector
- THASEEGARAN PILLAY, M.D.Executive Officer
- DAVID RICHMONDDirector
- ANDREW HINSONDirector
- WILLIAM ABBOTTExecutive Officer
- MICHAEL TAGLICHDirector
- RAYMOND COHENDirector
- Offering amount
- $10M
- Amount sold
- $1M
- Sales commissions
- $700K
- Proceeds to insiders
- $2M
- Placement agents
- TAGLICH BROTHERS, INC.
- First sale
- Apr 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6MraisedJan 2022 · 5 investors · OtherRule 506(b)
▶$6MraisedJan 2022 · 5 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- MARK RAVICHDirector
- WILLIAM ABBOTTExecutive Officer
- STEVEN HEALYDirector
- MICHAEL TAGLICHDirector
- JAMES DILLONExecutive Officer, Director
- GEORGE FAZIODirector
- DAVID RICHMONDDirector
- RAYMOND COHENDirector
- RINDA SAMADirector
- ANDREW HINSONDirector
- Offering amount
- $6M
- Amount sold
- $6M
- First sale
- Jan 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$40.8MraisedAug 2021 · 186 investors · OtherRule 506(b)
▶$40.8MraisedAug 2021 · 186 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- JAMES DILLONExecutive Officer, Director
- GEORGE FAZIODirector
- MARK RAVICHDirector
- RAYMOND COHENDirector
- WILLIAM ABBOTTExecutive Officer
- NOEL MESSENGERExecutive Officer
- DAVID RICHMONDDirector
- RINDA SAMADirector
- ANDREW HINSONDirector
- CHRISTOPHER WOLFFExecutive Officer
- MICHAEL TAGLICHDirector
- THASEEGARAN PILLAY, M.D.Executive Officer
- Offering amount
- $45M
- Amount sold
- $40.8M
- Sales commissions
- $1.4M
- Proceeds to insiders
- $2M
- Placement agents
- TAGLICH BROTHERS, INC.
- First sale
- Dec 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Rf Surgical5 shared keywordsMedtronic is a healthcare technology company that develops medical devices and technologies — including pacemakers, robotic-assisted surgery systems, and AI-driven health tools — used by doctors, scientists, and engineers to treat pain and disease. It works with clinicians to create solutions aimed at treating conditions such as AFib.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Ancora Heart3 shared keywordsAncora Heart develops minimally invasive medical devices, including a class III implantable therapy for cardiovascular treatment. The company focuses on cardiac/heart failure therapy development, clinical research, and commercialization of its core technology.
Alleviant Medical Inc3 shared keywordsAlleviant Medical develops an investigational minimally invasive medical device using interatrial shunt therapy to treat heart failure patients, currently in FDA-approved clinical trials (ALLAY-HF and ALLAY-HFrEF).
Companies competing with Bioventrix for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Bioventrix do?
- BioVentrix is a medical device company that develops less invasive therapies to treat heart failure by reconstructing the dilated left ventricle using myocardial micro-anchor implants. The company serves cardiothoracic surgeons and patients with ischemic heart failure.
- Who are Bioventrix's investors?
- Bioventrix's investors include Andera Partners.
- How much funding has Bioventrix raised?
- Bioventrix has disclosed $173.3M raised across 16 of its 17 known rounds.
- Where is Bioventrix headquartered?
- Bioventrix is headquartered in Mansfield, US.